linjc16/ctgov huggingface dataset:
Assessment of Cyclofusion Capabilities of Normal Subjects and Patients With 3D Dynamic Random-dot Stereograms

Study Overview
=================
Brief Summary
-----------------
With this study the investigator wants measure the individual cyclofusion competence from healthy subjects and patients suffering from Strabismus with a only binocularly visible threedimensional Landolt-C stimulus. For this the participant has to look at a 3-D monitor with shutter glasses. The participant is sitting in 2 meter distance in front of the monitor. On the monitor appears the Landolt-C stimulus as a dynamic Random-Dot Stimulus. As long as the participant can fuse the stimulus he will be able to see the Landolt C-ring threedimensional. The participant is then ask to tell in which direction the notch of the Landolt-C ring points out. Once a critical degree of cyclotorsion is reached the participant will no longer be able to see the Landolt C ring and the individual cyclofusion competence is reached.

Official Title
-----------------
Assessment of Cyclofusion Capabilities of Normal Subjects and Patients With 3D Dynamic Random-dot Stereograms

Conditions
-----------------
Cyclofusion Competence

Intervention / Treatment
-----------------
* Diagnostic Test: measurement of the cyclofusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Visual acuity >0,4; Stereopsis Exclusion Criteria: Visual acuity <0,4; no Stereopsis

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cyclofusion<br> | Diagnostic Test: measurement of the cyclofusion<br>* Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In- and excyclofusion competence in healthy individuals. Change in In- and excyclofusion competence in patients who need a strabismus surgery before and 6 month after surgery. | The maximum in- and maximum excyclofusion competence will be measured with the described test set-up. The results will be documented in degree. | Once in healthy individuals. Before and 6 month after a (independent from the study) performed strabismus surgery. |
COVID-19 Prevalence in HIV-infected Patients

Study Overview
=================
Brief Summary
-----------------
North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them figuring different kinds of immune deficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, those patients with uncontrolled viral load and/or low CD4 cell counts, remain at higher risk of severe COVID infection. In this context, the primary objective of our study is aimed at evaluating the prevalence of SARS-CoV-2 antibodies in a cohort of HIV-infected patients followed-up in an HIV-infection care center. Secondary objectives are: evaluating whether the antibodies are protective or not, the kinetic of these antibodies, and HIV associated factors with the presence of antibodies.

Official Title
-----------------
Seroprevalence of SARS-CoV-2 Antibodies Among Adult Patients Living With HIV

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Other: Blood Sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults (> 18 years) HIV-infected patients subjects with social insurance subjects able to understand study purposes, and to give a written and informed consent Exclusion Criteria : subjects unable to understand informations on the study, and to provide informed consent subjects under guardianship or curatorship subjects under judicial protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIV-infected patients<br>All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination | Other: Blood Sample<br>* Blood Sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Seroprevalence of SARS-CoV-2 | SARS-CoV-2 antibodies will be detected with a rapid test detecting IgG and IgM, at inclusion, and during a 6-month and a 12-month visit, in order to assess the prevalence of the virus in this population. | From baseline to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV-infection, AIDS, antiretroviral treatment, CD4 cell count, plasma HIV, RNA, SARS-CoV-2, antibodies
Microvascular Coronary Resistance and Absolute Coronary FLOW in Patients With Percutaneous Intervention of a Chronic Total Occlusion

Study Overview
=================
Brief Summary
-----------------
It is an observational study which objective is to analyze, through a series of invasive parameters, the state of the coronary microvasculature immediately after the successful percutaneous coronary intervention of a chronic total occlusion and at 6 months after the index procedure. The aim of the study is to check the variation in the values of the index of microcirculatory resistance (IMR) and invasive absolute coronary flow (AF). The working hypothesis is that, in the follow-up of these patients, AF will increase significantly with respect to its baseline and, conversely, IMR will be reduced during the follow-up.

Official Title
-----------------
Evolución de Las Resistencias Microvasculares y Del Flujo Coronario Absoluto en Pacientes Con intervención Coronaria percutánea de Una oclusión crónica

Conditions
-----------------
Chronic Total Occlusion of Coronary Artery, Microvascular Coronary Artery Disease, Coronary; Ischemic, Coronary Microvascular Dysfunction

Intervention / Treatment
-----------------
* Diagnostic Test: Invasive coronary physiology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Those patients with a clinical indication for percutaneous coronary intervention of a chronic total occlusion. As a routine clinical practice in our center, it is proposed to perform a angiographic follow-up 6 months after the index procedure. Exclusion Criteria: No specific exclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Global cohort<br>Invasive coronary physiology parameters estimation, including: FFR, CFR, IMR, Absolute coronary flow (AF). AF derived resistances | Diagnostic Test: Invasive coronary physiology<br>* Estimation of guide-wire coronary physiology parameters<br>* Other names: AF-derived coronary resistance;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation in the values of IMR between basal and 6-months follow-up |  | 6 months | 
| Variation in the values of absolute coronary flow between basal and 6-months follow-up |  | 6 months |
Ti PC Software for Analyzing Longitudinal Data

Study Overview
=================
Brief Summary
-----------------
To develop TI (pronounced 'T-sub-I'), a personal computer program to analyze time-varying data generated by periodic patient reports, repeatedly-observed disease signs, or serial biomarkers to study chronic disease.

Detailed Description
-----------------
BACKGROUND: With the advent of quasi-likelihood, generalized estimating equations, and new ways to handle missing data, has come a striking increase in applicable models, perhaps more than after the 1972 introduction of the Cox model for survival data. TI provided a way to analyze the data. DESIGN NARRATIVE: TIl provided graphics for data exploration and model validation. TI ran under most current version of Windows, used Civilized Software's MLAB as its programming language, offered context-sensitive help, a dictionary of relevant terms, identification of file entries from their screen position, and simple animation. TI permitted the user to analyze time-varying data from the two perspectives of repeated measured using a variety of models and time series where both time and frequency domain tools were provided. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Hypolipidemic Effect of Adansonia Digitata

Study Overview
=================
Brief Summary
-----------------
Adansonia digitata L. (AD) also known as Baobab is a huge tree that grows in many countries in sub-Saharan Africa. Many studies talking about AD biological activity including hypolipidemic, antioxidant and antimicrobials in animal's but not in human, This study will be undertaken to examine the effect of AD juice consumption against lipid profiles in traditional users and blood samples will be collected form participant's for investigated of lipid profiles pre and post AD juice drinking and the results will be compared.

Official Title
-----------------
Hypolipidemic, Antioxidant Activity of Adansonia Digitata Juice Consumption

Conditions
-----------------
Hyperlipidemias

Intervention / Treatment
-----------------
* Dietary Supplement: Adansonia digitata


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tradition users (drink AD juice) Exclusion Criteria: Diabetes, hypertension, or chronic illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2<br>Adansonia digitata (Baobab) | Dietary Supplement: Adansonia digitata<br>* Juice of AD fruit<br>* Other names: Baobab;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease cholesterol level | Hypolipidemias | 6 month's |
Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients

Study Overview
=================
Brief Summary
-----------------
This study is phase 3 study for prevention of VTE in patients with abdominal surgery.

Official Title
-----------------
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism (VTE) After Abdominal Surgery

Conditions
-----------------
Venous Thromboembolism

Intervention / Treatment
-----------------
* Drug: Fondaparinux sodium
* Drug: GSK576428


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients aged >=40 years undergoing the following abdominal (diaphragm to pelvic floor) surgery under general anesthesia lasting more than 45 minutes. General or urologic surgery Cancer surgery Gynecologic surgery Radical surgery for pelvic malignancy Exclusion criteria: Active, clinically significant bleeding Thrombocytopenia Body weight <40kg

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fondaparinux sodium|nan|
|Drug: GSK576428|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Venous thromboembolism and Major bleeding |  | Throughout entire study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Pulmonary embolism Incidence of Deep vein thrombosis Incidence of symptomatic Venous thromboembolism |  | Throughout entire study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fondaparinux Abdominal surgery Japanese VTE
The Effects of Dietary Fiber in CKD: A Systematic Review and Meta-analysis

Study Overview
=================
Brief Summary
-----------------
Chronic kidney disease (CKD) is a debilitating condition in which there is a gradual decline of renal function associated with increased overall mortality. Most dietary guidelines for CKD focus on limiting protein intake (nitrogen) and high phosphorus-containing foods. However, increasing dietary fiber has been proposed to increase fecal nitrogen excretion which may ameliorate the progress of CKD. We therefore plan to conduct a systematic review and meta-analysis on clinical trials to assess the effect of fiber on urea and creatinine as classical markers of a state of uremia in individuals with CKD. We hypothesize that increasing fiber intakes will improve urea and creatinine levels in individuals with CKD.

Official Title
-----------------
The Effects of Dietary Fiber on Uremic Retention Solutes in CKD: A Systematic Review and Meta-analysis

Conditions
-----------------
Chronic Kidney Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dietary trials in humans Randomized treatment allocation Suitable control (low fiber) viable endpoint data Exclusion Criteria: Non-human studies Nonrandomized treatment allocation Lack of a suitable control (high protein) no viable endpoint data
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic Kidney Disease<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Creatinine |  | 1.5 years | 
| urea |  | 1.5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phosphorus |  | 1.5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
The effects, dietary, fiber, kidney function, CKD patients
Arm Function and Quality of Life Following Mastectomy.

Study Overview
=================
Brief Summary
-----------------
To measure arm function and quality of life of mastectomy patients.

Detailed Description
-----------------
Treatment: Randomized to one of two treatment arms. Group One: Basic active exercise program at home. Group Two: Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises. Range of Motion measurements will be taken at the first session, 1 month, 6 weeks, 3 months, 6 months and 1 year. Patients will complete demographic form, functional questionnaire, and QOL questionnaire.

Official Title
-----------------
Arm Function and Quality of Life Following Mastectomy.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: Arm exercises.
* Procedure: Arm Exercises


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been referred from UNMH to CRTC for further treatment following mastectomy/lumpectomy surgery. Exclusion Criteria: Not specified
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group1<br> | Procedure: Arm exercises.<br>* Basic active exercise program at home.<br>|
| Experimental: Group 2<br> | Procedure: Arm Exercises<br>* Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arm Function and Quality of Life Following Mastectomy |  | Motion measurements will be taken at the first session, 1 month, 6 weeks, 3 months, 6 months and 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Supportive, Mastectomy, Quality of Life, Arm Function
Cardiac Diseases With Pregnancy in Benisuef Localities

Study Overview
=================
Brief Summary
-----------------
The aim of this work is to demonstrate the variation of cardiac diseases among pregnant ladies in our localities, detect maternal & fetal complications and to predict the risk factors for poor maternal, fetal & neonatal outcomes

Official Title
-----------------
Cardiac Diseases With Pregnancy in Benisuef Localities

Conditions
-----------------
Heart Disease Structural Disorder Abscess of Cardiac Septum

Intervention / Treatment
-----------------
* Other: registry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria All pregnant ladies with Cardiac diseases, valvular heart disease, congenital heart disease, ischemic heart disease, cardiomyopathy, arrhythmias , big and pulmonary hypertension, presenting with pregnancy regardless age, any concomitant diseases and type of heart disease will be enrolled. A similar number of pregnant females free from previous mentioned cardiac diseases will be studied as controls. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cardiac patients WHO class 1,2<br> | Other: registry<br> <br> |
| cardiac patients WHO class 3,4<br> | Other: registry<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetomaternal and neonatal outcome | Number of Participants With abortion,preterm labour,Intrauterine fetal death,Postterm fetus, intrauterine growth restriction,Fetuses with Congenital heart diseases,Neonatal admission to Neonatal Intensive care unit,neonatal death,Perineal,vaginal,broad ligament haematoma, Internal Hemorrhage due to anticoagulant drugs,malfunctioning valve,heart failure ,Thromboembolic complications, perinatal maternal death. | 2 years |
Cell Therapy in Limb Girdle Muscular Dystrophy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to study the effect of stem cell therapy on Limb Girdle Muscular Dystrophy patients.

Official Title
-----------------
Intrathecal Autologous Mononuclear Cell Therapy for Limb Girdle Muscular Dystrophy

Conditions
-----------------
Limb Girdle Muscular Dystrophy

Intervention / Treatment
-----------------
* Biological: Stem Cell


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age group of 15 years-60 years limb girdle muscular dystrophy diagnosed on the basis of clinical presentation Electromyographic and Nerve Conduction velocity findings Exclusion Criteria: presence of respiratory distress presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus malignancies acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30% pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stem Cell<br> | Biological: Stem Cell<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Functional Independence Measure (FIM) scale | Functional Independence Measure scale assesses the patients ability to carry out activities of daily living. At the follow up of 1 year, every patient in this study will be reevaluated on this scale. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Manual Muscle Testing (MMT) | Manual muscle testing is a procedure for the evaluation of the function and strength of individual muscles and muscle groups based on the effective performance of a movement in relation to the forces of gravity and manual resistance. On the follow up after 1 year, every patient will be reassessed on MMT to record changes in their muscle strength after stem cell therapy. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Limb Girdle Muscular Dystrophy, Autologous Bone Marrow Mononuclear cell therapy, Stem Cell